Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta

被引:32
作者
Lowing, Kristina [1 ]
Astrom, Eva [1 ]
Oscarsson, Katarina Allbrink [1 ]
Soderhall, Stefan [1 ]
Eliasson, Ann-Christin [1 ]
机构
[1] Karolinska Inst, Astrid Lindgren Hosp, Dept Woman & Child Hlth, S-10401 Stockholm, Sweden
关键词
activity; bisphosphonates; children; osteogenesis imperfecta;
D O I
10.1111/j.1651-2227.2007.00390.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI). Methods: In a prospective observational study, monthly intravenous pamidronate infusions were given to 43 children (aged 4 months-16 years) with different severity and form of OI. Outcome measures included the Pediatric Evaluation of Disability Inventory (PEDI), a score of well-being, registration of days with pain and bone density measured by using dual energy X-ray absorptiometry (DXA). Data were collected before and after the first year of treatment. Results: Self-care and mobility measured by PEDI increased significantly in both the Functional Skill scale and in the Caregiver Assistance scale. The youngest children improved more than the older ones according to the PEDI. The days with skeletal pain were reduced and both well-being and bone density increased. Conclusions: Intravenous treatment with bisphosphonates influenced health status, according to the International Classification of Functioning, Disability and Health (ICF). This group of 43 children experienced beneficial effects on everyday activities, skeletal pain, well-being and bone density.
引用
收藏
页码:1180 / 1183
页数:4
相关论文
共 26 条
[1]   Biphosphonates [J].
Allgrove, J .
ARCHIVES OF DISEASE IN CHILDHOOD, 1997, 76 (01) :73-75
[2]   Functional analysis of upper limb deformities in osteogenesis imperfecta [J].
Amako, M ;
Fassier, F ;
Hamdy, RC ;
Aarabi, M ;
Montpetit, K ;
Glorieux, FH .
JOURNAL OF PEDIATRIC ORTHOPAEDICS, 2004, 24 (06) :689-694
[3]  
Åström E, 1998, ACTA PAEDIATR, V87, P64
[4]   Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta [J].
Åström, E ;
Söderhäll, S .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 86 (05) :356-364
[5]  
Binder H, 1995, Connect Tissue Res, V31, pS37, DOI 10.3109/03008209509116831
[6]  
BOONEKAMP PM, 1986, BONE MINER, V1, P27
[7]   RADIOLOGICAL MANIFESTATIONS OF BISPHOSPHONATE TREATMENT WITH APD IN A CHILD SUFFERING FROM OSTEOGENESIS IMPERFECTA [J].
DEVOGELAER, JP ;
MALGHEM, J ;
MALDAGUE, B ;
DEDEUXCHAISNES, CN .
SKELETAL RADIOLOGY, 1987, 16 (05) :360-363
[8]   Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta [J].
DiMeglio, LA ;
Peacock, M .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (01) :132-140
[9]   Osteogenesis imperfecta in childhood: Impairment and disability. A prospective study with 4-year follow-up [J].
Engelbert, RH ;
Uiterwaal, CS ;
Gerver, WJ ;
van der Net, JJ ;
Pruijs, HE ;
Helders, PJ .
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2004, 85 (05) :772-778
[10]  
ENGELBERT RHH, 1997, PEDIAT PHYS THER, V9, P18